Legend Biotech (LEGN) Capital Expenditures (2020 - 2025)
Legend Biotech (LEGN) posted Capital Expenditures of -$5.0 million for Q3 2025, up 45.74% on a QoQ basis from -$9.2 million in Q2 2025, and down 142.37% year-over-year from $11.8 million in Q3 2024.
Legend Biotech (LEGN) has 6 years of Capital Expenditures data on file, last reported at -$5.0 million in Q3 2025.
- In Q3 2025, Capital Expenditures fell 142.37% year-over-year to -$5.0 million; the TTM figure through Sep 2025 stood at $9.6 million (down 60.16% YoY), while the FY2024 annual figure was $14.1 million, down 29.77% from the prior year.
- Capital Expenditures advanced to -$5.0 million in Q3 2025, from -$9.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $35.8 million in Q4 2023 and bottomed at -$42.2 million in Q4 2021.
- A 5-year average of -$5.3 million and a median of -$5.4 million in 2023 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 271.18% in 2023, down 1990.68% in 2023.
- Year by year, Capital Expenditures stood at -$42.2 million in 2021, then jumped by 50.41% to -$20.9 million in 2022, then soared by 271.18% to $35.8 million in 2023, then decreased by 27.89% to $25.8 million in 2024, then slumped by 119.38% to -$5.0 million in 2025.
- The last three Capital Expenditures figures came in at -$5.0 million (Q3 2025), -$9.2 million (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 786,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -5.01 Mn |
| Sep 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -9.22 Mn |
| Jun 30, 2025 | -9.22 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | 25.83 Mn |
| Dec 31, 2024 | 25.83 Mn |
| Sep 30, 2024 | -2.07 Mn |
| Sep 30, 2024 | -2.07 Mn |
| Jun 30, 2024 | -3.42 Mn |
| Jun 30, 2024 | -3.42 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | 35.82 Mn |
| Dec 31, 2023 | 35.82 Mn |
| Sep 30, 2023 | -5.38 Mn |
| Sep 30, 2023 | -5.38 Mn |
| Jun 30, 2023 | -6.09 Mn |
| Jun 30, 2023 | -6.09 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -20.93 Mn |
| Dec 31, 2022 | -20.93 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Sep 30, 2022 | -2.58 Mn |
| Jun 30, 2022 | 322,000.00 |
| Jun 30, 2022 | 322,000.00 |
| Mar 31, 2022 | -12.12 Mn |
| Mar 31, 2022 | -12.12 Mn |
| Dec 31, 2021 | -42.20 Mn |
| Dec 31, 2021 | -42.20 Mn |
| Sep 30, 2021 | -11.48 Mn |
| Sep 30, 2021 | -11.48 Mn |
| Jun 30, 2021 | -13.52 Mn |
| Jun 30, 2021 | -13.52 Mn |
| Mar 31, 2021 | -15.41 Mn |
| Mar 31, 2021 | -15.41 Mn |
| Dec 31, 2020 | -26.25 Mn |
| Dec 31, 2020 | -26.25 Mn |
| Sep 30, 2020 | -7.10 Mn |
| Sep 30, 2020 | -7.10 Mn |